healthcare drugs pharma

Two big sales totalling $2.1B could spark significant trading interest in Canada'a Valeant Pharmaceuticals today. The beleaguered company has agreed to sell three skin care brands to France's L'Oreal for $1.3B, and it's Dendreon Pharmaceuticals business to China's Sanpower Group for $820 million. Proceeds are expected to be used to pay down some of the $30B in debt the company has racked up over the years. Today's market reaction may indicate if the street sees this as the start of righting the ship or a sign of desperation. Selling Dendreon at a profit appears to be a step in the right direction but time will tell.


With the Dow slipping away from 20,000 and little in the way of economic or earnings reports, the focus for trading this week so far has turned to politics, particularly in the UK and the US.

Global markets have been consolidating yesterday's moves overnight. Gold and JPY have been holding on to their gains.

GBP is lower again although the pace of the sterling selloff has slowed. Brexit has been back in focus even though nothing has changed mainly because traders have nothing else to focus on at the moment. Traders should note the weaker pound continues to improve the competitiveness of the UK relative to the Eorozone and that it's only a matter of time before something else pops up and attention turns elsewhere.

US index futures and the Dax are flat so far today while the FTSE is up 0.4%. The Hang Seng rallied 0.8% while copper is up 1.0% as traders viewed rising Chinese producer prices as a sign of higher demand for commodities. 

Crude oil is bouncing back a bit from Monday's big selloff with WTI gaining 0.6%. Ongoing reports that OPEC and Non-OPEC producers are starting to cut production as promised has been offset by ongoing concerns that higher prices could bring shut-in US shale production back on-line. This week's API (tonight) and DOE reports could give a better idea of where the US market is at after last week's big swings that were distorted by year-end adjustments.

The big moves in indices and currencies that dominated late 2016 were driven by repositioning for Trump Administration. The street now appears to have fully priced in the upside of Trump putting the balance of risks to the downside for USD and US stocks. 

‎Tomorrow's press conference and the inauguration on January 20th could start the shift from speculating on what he could do to reacting to what he actually does. Today brings outgoing President Obama’s farewell speech where the street will looking to see if he decides to go out graciously or continues his recent program of Scorched Earth/try to make things difficult for Trump. 
This could determine if Donald Trump will be able to spend his first days in office moving forward his own agenda or having to put out the fires President Obama leaves behind. (Likely a combination of both) 


Corporate News

Valeant Pharmaceuticals    has agreed to sell a number of its products to businesses in France and China for $1.2B to raise money for debt repayment
WestJet Airlines    December traffic up 9.1% over year outpacing 7.1% capacity increase, load factor up to 80.8%


Economic News

China consumer prices        2.1% vs street 2.3%
China producer prices        5.5% vs street 4.5%

Norway consumer prices    3.5% vs street 3.9%
Norway producer prices        7.2% vs previous (2.6%)

Sweden industrial production    1.2% vs street 1.5%

France industrial production    1.8% vs street (0.2%)
France manufacturing prodn    2.3% vs street 0.7%


Australia retail sales        0.2% vs street 0.4%

There are no major economic reports scheduled for Europe or North America Tuesday. 

Upcoming significant economic announcements include:


8:15 am EST        Canada housing starts        street 190K

11:30 am EST        NZ QV house prices        previous 12.4%

4:30 pm ESTish        US API crude oil inventories

TBA             US Obama farewell speech


CMC Markets is an execution only service provider. The material (whether or not it states any opinions) is for general information purposes only, and does not take into account your personal circumstances or objectives. Nothing in this material is (or should be considered to be) financial, investment or other advice on which reliance should be placed. No opinion given in the material constitutes a recommendation by CMC Markets or the author that any particular investment, security, transaction or investment strategy is suitable for any specific person.